Seroquel XR sNDA For Depression, Anxiety On Track For 1H 2008 Following Positive Phase III Data
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca tells DAILY that despite the crowded market for depression and anxiety therapies, quetiapine would appeal to patients whose current treatments inadequately control symptoms.
You may also be interested in...
AstraZeneca Submits First Atypical Antipsychotic For Anxiety Indication
Supplemental NDA package for Seroquel XR includes data from four clinical studies, all of which met their primary endpoints.
AstraZeneca Submits First Atypical Antipsychotic For Anxiety Indication
Supplemental NDA package for Seroquel XR includes data from four clinical studies, all of which met their primary endpoints.
AstraZeneca Submits Seroquel XR sNDA For Major Depressive Disorder
Firm looks to expand $4 billion franchise into lucrative MDD market.